PHO: New study demonstrates that tumor removal in the outpatient setting is as good as TURBT under general anesthesia
2022-09-20 07:30:10
Press release - Oslo, Norway, September 20th, 2022: Photocure ASA, The Bladder
Cancer Company, announces the publication of first results from the Laser III
clinical study in the medical journal, European Urology. The study is part of a
systematic program aimed at verifying the safe treatment of bladder tumors in
the outpatient setting. Laser III results demonstrate the non-inferiority of
outpatient laser-mediated destruction of bladder tumors in conjunction with blue
light cystoscopy (BLC[®]) and Hexvix[®] versus inpatient BLC TURBT* under
general anesthesia. Photocure has supported this program and the specific study
since 2016.
Laser III is a prospective, randomized, non-inferiority trial conducted in the
Capital Region of Denmark from 2016 to 2020 (NCT02886026). Patients with
histologically verified Ta low-grade bladder tumor recurrence were enrolled. A
total of 206 patients were randomized